Table 1. Demographics and clinicopathological characteristics in propensity score matched patients.
| Factors | All patients | Matched patients | |||||
|---|---|---|---|---|---|---|---|
| Perioperative chemotherapy (n=43) | Surgery first (n=135) | P | Perioperative chemotherapy (n=43) | Surgery first (n=86) | P | ||
| Age (yr) | 53.0 (46.0–60.0) | 59 (48.0–65.3) | 0.048 | 53.0 (46.0–60.0) | 57.0 (47.0–64.0) | 0.240 | |
| Sex | 0.563 | 0.684 | |||||
| Male | 29 (67.4) | 98 (72.6) | 29 (67.4) | 61 (70.9) | |||
| Female | 14 (32.6) | 37 (27.4) | 14 (32.6) | 25 (29.1) | |||
| Charlson/Deyo comorbidity score | 0.927 | 0.895 | |||||
| 0 | 34 (79.1) | 103 (76.3) | 34 (79.1) | 69 (80.2) | |||
| 1 | 8 (18.6) | 29 (21.5) | 8 (18.6) | 14 (16.3) | |||
| 2 | 1 (2.3) | 3 (2.2) | 1 (2.3) | 3 (3.5) | |||
| BMI (kg/m2) | 22.9 (20.3–25.0) | 22.9 (20.4–25.0) | 0.798 | 22.9 (20.3–25.0) | 22.6 (20.4–24.6) | 0.693 | |
| Previous abdominal surgery history | 0.999 | 0.999 | |||||
| Absent | 41 (95.3) | 128 (94.8) | 41 (95.3) | 81 (94.2) | |||
| Present | 2 (4.7) | 7 (5.2) | 2 (4.7) | 5 (5.8) | |||
| Location of tumor | 0.031 | 0.172 | |||||
| Lower third | 15 (34.9) | 54 (40.0) | 15 (34.9) | 33 (38.4) | |||
| Middle third | 5 (11.6) | 25 (18.5) | 5 (11.6) | 11 (12.8) | |||
| Upper third | 7 (16.3) | 5 (3.7) | 7 (16.3) | 4 (4.7) | |||
| Combined | 16 (37.2) | 51 (37.8) | 16 (37.2) | 38 (44.2) | |||
| Morphology | 0.454 | 0.530 | |||||
| Superficial | 0 (0) | 5 (3.7) | 0 (0) | 4 (4.7) | |||
| Borrmann type I | 0 (0) | 2 (1.5) | 0 (0) | 0 (0) | |||
| Borrmann type II | 5 (11.6) | 27 (20.0) | 5 (11.6) | 11 (12.8) | |||
| Borrmann type III | 36 (83.7) | 96 (71.1) | 36 (83.7) | 68 (79.1) | |||
| Borrmann type IV | 2 (4.7) | 5 (3.7) | 2 (4.7) | 3 (3.5) | |||
| Histology | 0.360 | 0.504 | |||||
| Differentiated | 12 (27.9) | 49 (36.3) | 12 (27.9) | 29 (33.7) | |||
| Undifferentiated | 31 (72.1) | 86 (63.7) | 31 (72.1) | 57 (66.3) | |||
| Clinical T classification | 0.047 | 0.291 | |||||
| T2 | 0 (0) | 14 (10.4) | 0 (0) | 5 (6.0) | |||
| T3 | 39 (70.9) | 113 (83.7) | 39 (70.9) | 75 (87.2) | |||
| T4 | 4 (9.3) | 8 (5.9) | 4 (9.3) | 6 (7.0) | |||
| Clinical N classification | 0.328 | 0.393 | |||||
| N0 | 0 (0) | 2 (1.5) | 0 (0) | 2 (2.3) | |||
| N1 | 21 (48.8) | 67 (49.6) | 21 (48.8) | 37 (43.0) | |||
| N2 | 20 (46.5) | 65 (48.1) | 20 (46.5) | 46 (53.5) | |||
| N3 | 2 (4.7) | 1 (0.7) | 2 (4.7) | 1 (1.2) | |||
| Clinical stage* | 0.211 | 0.666 | |||||
| IIIA | 20 (46.5) | 78 (57.8) | 20 (46.5) | 41 (47.7) | |||
| IIIB | 18 (41.9) | 50 (37.0) | 18 (41.9) | 39 (45.3) | |||
| IV | 6 (11.6) | 7 (5.2) | 5 (11.6) | 6 (7.0) | |||
Values are presented as median (IQR) or number of patients (%).
BMI = body mass index; IQR = interquartile range.
*The Japanese classification, 2nd English Edition [16].